1. Trypanosoma cruzi P21: a potential novel target for chagasic cardiomyopathy therapy.
- Author
-
Machado, Fabrício Castro, Teixeira, Thaise Lara, Alves da Silva, Aline, Teixeira, Samuel Cota, Borges, Bruna Cristina, dos Santos, Marlus Alves, Martins, Flávia Alves, Brígido, Paula Cristina, Rodrigues, Adele Aud, Notário, Ana Flávia Oliveira, Ferreira, Bruno Antônio, Servato, João Paulo Silva, Deconte, Simone Ramos, Araújo, Fernanda de Assis, Tomiosso, Tatiana Carla, Silva, Marcelo José Barbosa, da Silva, Claudio Vieira, Lopes, Daiana Silva, and Ávila, Veridiana Melo Rodrigues
- Subjects
TRYPANOSOMA cruzi ,CHAGAS' disease ,CARDIOMYOPATHIES ,AUTOIMMUNITY - Abstract
Chagas disease, which is caused by the parasite Trypanosoma cruzi, is an important cause of cardiomyopathy in Latin America. It is estimated that 10%-30% of all infected individuals will acquire chronic chagasic cardiomyopathy (CCC). The etiology of CCC is multifactorial and involves parasite genotype, host genetic polymorphisms, immune response, signaling pathways and autoimmune progression. Herein we verified the impact of the recombinant form of P21 (rP21), a secreted T. cruzi protein involved in host cell invasion, on progression of inflammatory process in a polyester sponge-induced inflammation model. Results indicated that rP21 can recruit immune cells induce myeloperoxidase and IL-4 production and decrease blood vessels formation compared to controls in vitro and in vivo. In conclusion, T. cruzi P21 may be a potential target for the development of P21 antagonist compounds to treat chagasic cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF